Premium
Neutropenia and anaemia due to carbimazole‐dependent antibodies
Author(s) -
Bux J.,
ErnstSchlegel M.,
Rothe B.,
Panzer C.
Publication year - 2000
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2000.01978.x
Subject(s) - carbimazole , antibody , neutropenia , medicine , cytopenia , immunology , platelet , bone marrow , chemotherapy , disease , graves' disease
Carbimazole‐dependent antibodies to erythrocytes were detected in the sera of three anaemic patients who had been treated with carbimazole for hyperthyroidism. By the use of Rh null ‐typed erythrocytes, we could show that some of these were directed against the proteins of the Rh complex. Carbimazole‐dependent antibodies eluted from erythrocytes showed no binding to other blood cells. One patient also presented with neutropenia and mild thrombocytopenia. Additional carbimazole‐dependent antibodies against the neutrophil‐specific Fcγ receptor IIIb (FcγRIIIb, CD16b) and the broadly expressed platelet endothelial cell adhesion molecule 1 (PECAM‐1; CD31) were detected in this patient's serum. Surprisingly, the PECAM‐1‐reactive drug‐dependent antibodies were also detectable in the sera of the other two patients with normal leucocyte and platelet counts. We assume that carbimazole can induce cell lineage‐specific drug‐dependent antibodies that cause cytopenia and also drug‐dependent antibodies against the broadly expressed PECAM‐1 molecule that may cause mild but not severe cytopenia.